NCT04556266 2025-05-13
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
Clinical Trials
24 trialsNCT06290622 2025-05-06
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02298816 2024-10-03
HMvax-Regist
Wake Forest University Health Sciences
Withdrawn
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT04995536 2024-04-25
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Phase 1 Withdrawn
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05613348 2024-03-18
CAR19T2
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05796271 2024-02-29
Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05929716 2023-11-13
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05513612 2023-03-01
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT04877080 2023-02-10
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1 Withdrawn
NCT05570188 2022-11-30
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
Phase 1/2 Withdrawn
NCT05015972 2022-11-29
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Withdrawn
NCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04665115 2022-08-03
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT04641806 2021-08-19
LYMPHO-Cov-2
Versailles Hospital
Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT03920631 2021-03-23
MicroBLITZ
Duke University
Phase 1 Withdrawn
NCT02547948 2020-07-16
CD19-targeting CAR T Cells for B Cell Lymphoma
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00837174 2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00210340 2015-03-30
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
International Extranodal Lymphoma Study Group (IELSG)
Phase 1 Withdrawn
NCT01044004 2013-07-23
Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue
Washington University School of Medicine
Phase NA Withdrawn